New breast cancer combo challenges standard treatment in major trial

This study is testing whether a new drug called HRS-8080, when combined with dalpiciclib, works better than the current standard treatment (fulvestrant with dalpiciclib) for advanced breast cancer that has become resistant to previous hormone therapies. It will involve about 912 women whose cancer has spread or returned after surgery and initial treatment. Researchers will measure how long the cancer stays under control and monitor side effects to determine which combination is safer and more effective.